VJOncology is committed to improving our service to you

GU Cancers 2018 | Straightforward study design: SPARTAN trial of apalutamide for nmCRPC

VJOncology is committed to improving our service to you

Eric Small

There has previously been no effective treatment for nonmetastatic castration-resistant prostate cancer (nmCRPC). Now there are several exciting late-phase clinical trials investigating promising treatments for nmCRPC, which are likely to be in the clinic soon. In this interview, Eric Small, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, provides an overview of the Phase III double-blind SPARTAN trial (NCT01946204), which tested apalutamide in this group. Dr Small explains the straightforward design of the study, including the inclusion criteria. This video was recorded at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter